APOA1 and autoimmune pancreatitis: Gene therapy through AAV vectors, liver-targeted mRNA-based approaches exploiting LNPs, and recombinant human PBGD combined with ApoA1 displayed well-tolerated and safe profiles in small and large experimental models of AIP, showing high hepatic tropism, little immunogenicity, and significant improvements in biochemical alterations, pain, and motor disability.